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ABSTRACT
While decades of research have identified molecular pathways inducing and 
promoting stages of prostate cancer malignancy, studies addressing dynamic changes 
of cancer-related regulatory factors in a prostate tumor progression model are limited. 
Using the TRAMP mouse model of human prostate cancer, we address mechanisms 
of deregulation for the cancer-associated transcription factors, Runx1 and Runx2 by 
identifying microRNAs with reciprocal expression changes at six time points during 
33 weeks of tumorigenesis. We molecularly define transition stages from PIN lesions 
to hyperplasia/neoplasia and progression to adenocarcinoma by temporal changes in 
expression of human prostate cancer markers, including the androgen receptor and 
tumor suppressors, Nkx3.1 and PTEN. Concomitant activation of PTEN, AR, and Runx 
factors occurs at early stages. At late stages, PTEN and AR are downregulated, while 
Runx1 and Runx2 remain elevated. Loss of Runx-targeting microRNAs, miR-23b-5p, 
miR-139-5p, miR-205-5p, miR-221-3p, miR-375-3p, miR-382-5p, and miR-384-5p, 
contribute to aberrant Runx expression in prostate tumors. Our studies reveal a 
Runx/miRNA interaction axis centered on PTEN-PI3K-AKT signaling. This regulatory 
network translates to mechanistic understanding of prostate tumorigenesis that can 
be developed for diagnosis and directed therapy.
INTRODUCTION
Prostate cancer (PCa) is the most diagnosed cancer 
among men in the United States and is the second leading 
cause of cancer-related deaths [1]. Numerous tumor-
derived human prostate cancer cell lines have elucidated 
mechanisms contributing to PCa cell phenotypes including 
the deregulation of oncogenes, tumor suppressors, 
and growth factors. Transcriptional regulators that 
activate biological pathways, such as the epithelial to 
mesenchymal transition (EMT), are well characterized 
to promote prostate tumorigenesis [2]. However, there 
still remains a gap in knowledge as to the mechanisms 
driving clinically relevant disease. The use of animal 
models that develop endogenous prostate tumors, such as 
the TRansgenic Adenocarcinoma of the Mouse Prostate 
(TRAMP) [3, 4], can add to our understanding of the 
mechanisms underlying PCa progression. Here, we report 
for the first time in TRAMP mice, dynamic expression 
changes of the transcription factors, Runx1 and Runx2, 
and microRNAs that contribute to deregulated expression 
of Runx proteins, during the transition of normal prostate 
tissue to adenocarcinoma.
Our laboratory, and others, have identified 
expression and functional activities of the Runx 
transcription factors in various cancers [5]. There is 
mounting evidence that Runx factors are transcriptional 
drivers of tumor progression [6]. Runx1 and Runx2 are 
expressed in the normal epithelium of exocrine glands 
[7], sites of origination for carcinomas. Both mutations 
[8, 9] and increased expression [10] of Runx1, a required 
factor for hematopoiesis, are associated with breast [11] 
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and lung [12] cancer tumors. Runx2, an essential “master 
regulator” for bone formation, is abnormally expressed 
in aggressive breast and prostate cancer and activates 
genes associated with tumorigenesis and metastasis 
[11, 13, 14]. In data generated by the TCGA Research 
Network: http://cancergenome.nih.gov/ and analyzed 
with cBioPortal [15-17], mutations in Runx1 and Runx2 
occur in 6.1% and 2.8%, respectively, of invasive breast 
carcinoma and, while these mutation rates are near 0% 
for prostate adenocarcinoma, the mRNA levels of Runx1 
and Runx2 increase 4.8% and 3.6%, respectively, in men 
with PCa. Further, men with castration resistant PCa and 
androgen-independent mouse prostate tumors upregulate 
Runx1 [18]. Further, Runx2 is reported to be expressed 
in nearly 50% of patients with primary prostate tumors 
or PCa-induced bone metastases [19]. In addition, Runx1 
and Runx2 are expressed in both early and late stage PCa-
derived cell lines and promote expression of the prostate 
specific antigen (PSA) [20]. Abnormally high levels of 
Runx2, and their targeted genes, in human prostate tissue 
and cells lines positively correlate with tumor stage and 
aggressiveness [19, 21]. Our previous studies, and those 
of other laboratories, have documented the osteomimetic 
properties of Runx2 in primary tumors and that inhibition 
of Runx2 in breast and prostate cancer cells blocks 
metastasis and osteolytic bone disease mediated by human 
tumor cells in orthotopic mouse models [19, 21-23].
MicroRNAs (miRNA) have emerged as important 
biomarkers for nearly all cancers with hundreds of 
discovered direct mRNA/miRNA interactions elucidating 
their functional activity in silencing protein expression 
of individual genes [11, 24]. Furthermore, miRNAs that 
directly target Runx2, but are missing in aggressive breast 
cancer cells, have been shown to be effective in disease 
intervention by a miRNA replacement approach in vivo 
[25]. Moreover, direct evidence implicates miRNAs in 
the development of prostatic tumors and progression 
through adenocarcinoma [26, 27]. Among the most well 
studied miRNAs that promote carcinogenesis, miR-21 is 
upregulated in more aggressive prostate tumors [28] and 
directly targets tumor suppressors resulting in activation 
of tumorigenic pathways [29-32]. On the contrary, miR-
203-3p is progressively downregulated in primary prostate 
tumors, is absent or lowly expressed in bone metastatic 
PCa cells and metastases, and suppresses Runx2 and other 
genes that promote PCa metastasis to bone [33]. Thus, 
miRNAs that target Runx1 or Runx2 and are deregulated 
during prostate tumorigenesis present exciting candidates 
for novel therapeutic intervention in men diagnosed with 
prostate cancer.
In the present studies, compelling questions 
related to temporal expression changes and functional 
significance of Runx1, Runx2, and Runx-targeting 
miRNAs were addressed in a true local progression model 
of PCa. The TRAMP mouse is ideal to study the dynamic 
expression of Runx1 and Runx2 in the transition from a 
normal gland to tumorigenic tissue as TRAMP prostates 
develop morphologically and histologically similar tumors 
to human prostate cancer [3, 4]. Common features of 
the TRAMP mouse and human prostate cancer include 
formation of prostatic intraepithelial neoplasia (PIN) 
lesions, transition to hyperplasia/neoplasia, progression to 
an adenocarcinoma and oftentimes mixed neuroendocrine 
disease, invasion of the surrounding tissue, and metastasis, 
most commonly to lung and peripheral lymphatic tissue 
[34-37]. To date, the TRAMP mouse has been widely used 
for validating dysregulated genes and their associated 
pathways in vivo and for testing novel inhibitors of 
prostate cancer progression [36]. However, previous 
studies primarily focused on histologic protein analyses 
of murine prostate tissue. Notably, a limited number of 
genome-wide gene expression studies are available and 
only end stage tumors in aged TRAMP animals with 
palpable and poorly differentiated tumors were examined 
[38, 39].
Here, we examine expression levels of known 
markers for early and advanced stages during prostate 
tumor progression in the TRAMP mouse to establish 
stages representing human PCa. In this context, we 
tested the hypothesis that aberrant Runx1 and Runx2 
expression involves a mechanism where small, non-coding 
microRNAs deregulate Runx levels resulting in increased 
downstream signaling to drive tumorigenesis. We further 
postulate that those genes regulated by Runx1, Runx2, and 
miRNAs targeting Runx form an interaction network that 
promotes PCa progression and may reveal distinct and/
or cooperative mechanisms (by Runx1/2) contributing to 
PCa. We find the androgen receptor and tumor suppressors, 
Nkx3.1 and PTEN, together define a transition from early to 
late stage disease in the TRAMP mouse. Runx1 and Runx2 
continuously increase while miRNAs with predicted or 
validated repression of Runx factors decrease during tumor 
progression. In addition, we identify PTEN-PI3K-AKT 
signaling as mediated by a Runx/miRNA interaction axis.
RESULTS
Gene expression changes indicate two phases of 
local prostate tumorigenesis
We isolated RNA from transgenic and non-
transgenic TRAMP mouse prostates spanning from 
adolescence, prior to histologic detection, through 
development of PIN lesions, hyperplasia, and 
adenocarcinoma (Supplementary Figure S1) [4]. 
Expression of Runx1 and Runx2 mRNA were assessed 
by qPCR at six time points in wild type and transgenic 
prostate lobes. By 12 weeks, when PIN lesions begin to 
appear (Supplementary Figure S1), Runx1 and Runx2 
are significantly upregulated in the TRAMP prostate 
compared to wild type animals and remain at elevated 
levels through 33 weeks (Figure 1A, 1B). Histone H4, a 
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marker of proliferation, while slightly elevated in TRAMP 
animals, remains constitutive through the time course in 
both wild type and transgenic mice, suggesting that the 
persistent increases of Runx1 and Runx2 in TRAMP 
prostates are not related to proliferative differences and 
likely result from prostatic tumorigenesis (Figure 1C).
As human prostate cancer advances, becoming more 
aggressive, response to hormone therapy is abrogated and 
the disease transitions to androgen independence, designated 
castration-resistant prostate cancer, leading to more invasive 
treatments and dramatically reduced quality of life [40]. The 
androgen receptor (AR) is more highly expressed in TRAMP 
prostates through initial disease development but is reduced 
by 21 weeks, remaining at similar levels in TRAMP and 
wild type prostates through 33 weeks (Figure 1D). This 
pattern of decreased AR in TRAMP mice may represent 
a transformation of the tumor to androgen independent 
disease. Thus, the TRAMP model provides an in vivo system 
for future study to elucidate molecular mechanisms involved 
in the transition to castration-resistant prostate cancer. AR 
has been directly tied to the expression of integrins in 
prostate cancer [41]. In addition, recent evidence implicates 
αvβ6-integrin in PCa progression, specifically in promoting 
an osteolytic program in metastatic tumor cells [21]. GEM 
models of prostate cancer do not develop metastatic bone 
lesions. Nonetheless, αvβ6-integrin is initially upregulated 
Figure 1: Gene expression changes in TRAMP prostate through disease progression. qPCR levels of Runx1 (A), Runx2 
(B), Histone H4 (C), androgen receptor (AR) (D), αvβ6-Integrin (E), Nkx3.1 (F), Pten (G), Tgf-β1 (H), and p21 (I) message in the ventral 
and lateral prostate lobes isolated from wild type (•) or TRAMP (□) animals. Animals were sacrificed at 6, 12, 16, 21, 28, and 33 weeks to 
follow tumor development. Both Runx1 (A) and Runx2 (B) transcriptional drivers of tumor progression are elevated in TRAMP prostates 
irrespective of animal age and increase throughout the time course. (A-C) Relative quantity calculated as 1/(2^(Ct,gene – Ct,18S)). (D-I) 
Relative expression calculated using the delta delta Ct method, 2^((Ct,gene – Ct,18S)wild type – (Ct,gene – Ct,18S)TRAMP), at each time point. 
All expression values normalized to 18S. N = 3 animals per time per genotype. Error bars are SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 
compared to wild type.
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more than 6-fold in TRAMP prostates, as compared to non-
transgenic mice, through the first 16 weeks, suggesting a role 
in disease onset and tumor development. Yet, by 21 weeks, 
levels are reduced to that of wild type mice (Figure 1E). In 
fact, this dip in expression is shared amongst other genes, 
including Runx1 and Runx2, and may indicate a dramatic 
shift in disease state occurring in TRAMP mice between 16 
and 21 weeks (Figure 1).
To determine if the changes observed in Runx1, 
Runx2, AR, and αvβ6-integrin correspond to PCa 
biomarkers indicative of disease stage, we assayed for 
Nkx3.1, Pten, Tgf-β1, and p21. The tumor suppressors 
Nkx3.1 and Pten play an important and integrative role in 
prostate cancer development and progression to metastatic 
bone disease. Nkx3.1 negatively regulates epithelial cell 
propagation and thus, down regulation of Nkx3.1 results in 
increased cellular proliferation leading to neoplasia (PIN 
lesions) and hyperplasia [42]. In striking contrast to wild 
type tissue, Nkx3.1 decreases continuously in TRAMP 
prostates, is repressed more than 2-fold through 21 weeks 
and nearly 15-fold by 28 weeks (Figure 1F). While levels 
of Pten mRNA increase almost 2-fold by week 16, its 
expression rapidly decreases by week 21 and remain 
low through the time course (Figure 1G). Loss of Pten is 
associated with the progression from a localized prostate 
carcinoma to invasive and metastatic adenocarcinoma [43].
Both Tgf-β1 and p21 have described dual roles as 
tumor promoters and suppressors in cancer [reviewed 
in 44, 45]. Transgenic animals exhibit increasing levels 
of these factors by at least 2-fold up to 16 weeks with a 
sharp decline at week 21 (Figure 1H, 1I). Tgf-β1 and p21, 
as well as αvβ6-integrin, spike again at 28 weeks, which 
may reflect a sub-population or new foci of tumor cells that 
recapitulates the upregulation observed at tumor onset. The 
increases in Tgf-β1 and p21 levels at the indicated time 
points are likely to be associated with oncogenic activity. In 
contrast, the return to wild type levels at 21 and 33 weeks 
may reflect functions tied to metastatic castration-resistant 
prostate cancer rather than the driver role of Tgf- β in early 
tumorigenesis. Consistent with this interpretation is that loss 
of Tgf- β leads to an increase in metastases in PTEN null 
mice as well as development of invasive prostate cancer in 
mice with constitutive AKT signaling [46]. Furthermore, 
p21 directly regulates PI3K/AKT activation and is AR 
responsive [47] suggesting that the low levels at 21 weeks 
is also contributing to a transition to androgen insensitive 
disease, as indicated above for the decrease in AR by 21 
weeks. In conclusion, we observe elevated Runx1 and 
Runx2 levels throughout disease progression that is 
associated with dynamic expression of PCa-associated 
genes (AR, αvβ6-integrin, Nkx3.1, Pten, Tgf-β1, and p21) 
that mark stages of prostate tumor development in the 
TRAMP mouse consistent with human disease.
Loss of Runx1 and Runx2 inhibits prostate cell 
motility
The persistent elevation of Runx1 and Runx2 
transcription factors in TRAMP prostate tissue throughout 
progression to adenocarcinoma suggests a pro-tumorigenic 
role in prostate cancer. Using the TRAMP-C2 cell line, 
which provides an in vitro model to elucidate molecular 
mechanisms of prostate cancer, we assessed the functional 
activities of Runx1 and Runx2 in PCa. Transfection of 
siRNAs against Runx1 and Runx2 in TRAMP-C2 cells 
reduces the area healed in response to a scratch wound 
made in the cell monolayer. Notably, inhibition of both 
Runx1 and Runx2 led to a 20% decrease in area healed 
by 12 hours as compared to non-targeting control, well 
before 100% closure of scratch wound (Figure 2). All 
Figure 2: Inhibition of Runx1 and Runx2 reduces motility of TRAMP prostate cells. The average area healed following a 
scratch wound in a monolayer of TRAMP-C2 cells is reduced following siRNA inhibition of Runx1 (red) or Runx2 (blue) as compared to 
non-targeting control (black) (A) Cells transfected with non-targeting control migrate to heal the wound by 16 hours while cells treated with 
siRunx1 or siRunx2 do not completely close the scratch (B) The threshold used to measure wound area is illustrated by the yellow highlights 
in each representative image. Three locations imaged per condition in three independent experiments from sequential cell passages. Error 
bars are SEM. * p < 0.05 compared to non-targeting control. Scale bar = 100μm.
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scratch wounds healed by 20 hours. This result would be 
expected given the similarity between the DNA-binding 
domain of Runx1 and Runx2 and their potential to regulate 
similar gene cohorts. In addition, inhibition of Runx1 in an 
in vitro breast cancer model reduces cell migration [22]. 
Inhibition of Runx2 by miRNAs that result in decreased 
PTK2 and ROCK1 signaling, contribute to cell motility 
[25], and another study directly identified by ChIP-Seq 
Runx2 binding to cell adhesion and motility-related genes 
[48]. These data, together with the temporal increase in 
expression of Runx1 and Runx2 during prostate tumor 
growth (Figure 1A, 1B), is indicative that Runx factors 
contribute to prostate cancer development and progression.
MicroRNAs targeting Runx1 and Runx2 
decrease in the TRAMP prostate
A question remains as to how abnormal levels 
of Runx factors are modulated during prostate cancer 
progression. The mechanism leading to an increase in 
Runx expression during prostate tumorigenesis may occur 
at the transcriptional or post-transcriptional level. As 
miRNAs directly control Runx expression [49, 50] and 
are established epigenetic regulators of cancer initiation, 
tumor progression, and metastasis, we postulate that 
miRNAs targeting Runx1 and/or Runx2 would have 
reciprocal expression in TRAMP prostates. Well over 50 
individual miRNAs are computationally predicted to target 
Runx1 and/or Runx2 (TargetScan v6.2). Of these miRNAs, 
28 candidates were selected for further interrogation in 
wild type and transgenic TRAMP prostates, representing 
the spectrum from novel to established PCa-association 
and repression of Runx1 and/or Runx2. To identify 
deregulated miRNAs targeting Runx in prostate cancer 
development and early tumorigenesis, miRNA expression 
levels were determined at 6, 12, 16, and 21 weeks by 
qPCR. Most miRNAs that target either or both Runx1 
and Runx2 decrease within this timeframe with ~25% of 
the candidates found to be significantly downregulated, 
reciprocal to increased levels of the Runx factors (Table 
1). Of note, several miRNAs reported to regulate Runx1 
and/or Runx2, such as miR-135a [50] and miR-203 [33], 
and are associated with invasive and metastatic PCa trend 
downwards but do not achieve significant differences 
between transgenic and non-transgenic animals. We 
conclude that these miRNAs likely contribute to advanced 
disease and distal metastasis, which are outside the scope 
of the TRAMP animal model.
Using the TRAMP mouse, we identify clinically 
relevant miRNAs targeting the Runx family (Figure 3). 
Several of these candidate miRNAs, such as miR-23b-5p 
[51] and miR-221-3p [52], have a characterized phenotype 
in PCa and are downregulated in malignant human tissue 
[53]. Four miRNAs target both Runx1 and Runx2 and 
are sharply downregulated by 12 weeks coincident with 
the peak levels of Runx factors (Table 1-bold and italic, 
Figure 3). These are miR-23b-5p and miR-205 which 
function as tumor suppressors in many ways [26, 51], 
miR-375-3p is well characterized as a valuable marker of 
disease progression for diagnosis and prognosis [reviewed 
in 54], and miR-384-5p. Currently, for miR-384-5p, there 
is no information related to cancer and therefore represents 
a potentially novel function in PCa. Similar downregulated 
expression patterns are observed for candidate miRNAs 
predicted to regulate either Runx1 or Runx2 (Table 1-
bold and italic, Figure 3). Runx1 is uniquely targeted by 
miR-139-5p and miR-382-5p, neither miRNA has been 
extensively examined in association with prostate cancer. 
One study showed that miR-139-5p secreted from primary 
prostate cancer cell cultures increased the expression of 
genes that can contribute to the invasive properties of 
PCa cell populations [55]. miR-382-5p has been reported 
to inhibit tumor growth and enhance chemosensitivity 
in osteosarcomas [56]. miR-221-3p, an established PCa 
tumor suppressor [52], uniquely targets Runx2. Together 
these miRNAs suggest complex and potentially redundant 
mechanisms to prevent dysregulation of Runx factors in 
the healthy prostate.
A Runx/miRNA interaction network drives 
prostate cancer
A combined Runx/miRNA regulatory network that 
promotes prostate carcinogenesis has not been previously 
described. To discover the molecular mechanisms through 
which Runx1, Runx2, and the Runx-targeting miRNAs, 
miR-23b-5p, miR-139-5p, miR-205-5p, miR-221-
3p, miR-375-3p, miR-382-5p, and miR-384-5p, drive 
prostate tumorigenesis, we interrogated well-accepted 
bioinformatics tools; DAVID [57, 58] and Ingenuity 
Pathway Analysis (IPA-www.ingenuity.com). Genes that 
interact with Runx1 (456 genes), Runx2 (525 genes), 
or the seven candidate miRNAs (ranging from 73 to 
>1000 targets) were identified in IPA. These genes were 
combined into a master list, List A (Supplementary Table 
S1), of Runx/miRNA (3569 genes) interacting factors. 
List A genes were imported into DAVID and annotated for 
function across numerous database. Enriched ontologies 
and biological pathways within the KEGG and PANTHER 
databases were determined and ranked by EASE score 
(Figure 4A). Seven of the top 10 enriched KEGG pathways 
are related to a specific cancer with Prostate cancer being 
the second most significant pathway with an over 3-fold 
enrichment as compared to all annotated genes (Figure 
4B). Moreover, interrogation of the PANTHER database 
identifies cancer (p53 and Ras) and bone (Wnt and TGF-β) 
related pathways, as well as many growth factors (PDGF, 
EGF, IGF, and VEGF), to be significantly enriched within 
the Runx/miRNA interaction network (Figure 4C).
We next mapped the genes in the interaction 
networks of Runx1, Runx2, coupled or linked to the seven 
candidate miRNAs (see Table 1 bolded miRNAs) onto 
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the Prostate Cancer Signaling (PCS) network within IPA 
(Figure 5). In addition to targeting Runx1 and Runx2, our 
candidate miRNAs regulate numerous other genes within 
the PCS network. While both Runx1 and Runx2 have 
unique interaction partners, orange and green highlighted 
genes respectively, many genes and miRNAs interact with 
both Runx1 and Runx2, highlighted in red. Two focal 
points are revealed, centered on PI3K/AKT/PTEN and cell 
growth control (p53/p27Kip1), as highlighted by blue boxes, 
suggesting potential mechanisms of action through which 
Runx factors and targeting miRNAs regulate prostate 
cancer. Upon query of data generated by the TCGA 
Research Network, AKT and PI3K tend towards co-
occurancy with Runx1 and Runx2, whereas PTEN tends 
Table 1: Expression of candidate miRNAs predicted to target Runx1 and Runx2 in TRAMP prostate over time 
miRNA Target Fold Difference
6wk 12wk 16wk 21wk
mmu-miR-20a-5p Runx1 1.15 1.63 1.65* -1.05
mmu-miR-20b-5p Runx1 1.00 1.44 1.48* 1.12
mmu-miR-23b-5p Runx1/Runx2 -1.22* -1.28 -1.61* -2.17
mmu-miR-27a-3p Runx1 -1.28 -1.10 -1.09 -1.45
mmu-miR-27b-3p Runx1 -1.06 -1.02 -1.25** -1.69
mmu-miR-30a-5p Runx1/Runx2 -1.19 -1.18 -1.01 -2.08
mmu-miR-30c-5p Runx1/Runx2 1.04 -1.09 -1.30 -2.13
mmu-miR-30e-5p Runx1/Runx2 -1.04 -1.08 1.04 -1.27
mmu-miR-93-5p Runx1 1.51* 2.08 2.27* 1.73*
mmu-miR-135a-5p Runx1/Runx2 -1.12 -1.39 -1.05 -1.56
mmu-miR-135b-5p Runx1/Runx2 -1.22 -1.67 -1.32 -1.39
mmu-miR-139-5p Runx1 -1.11 -1.67 -2.08* -1.75
mmu-miR-141-3p Runx1 -1.28 1.30 2.33 -1.49
mmu-miR-181a-5p Runx1 -1.04 -1.22 -1.33 -1.11
mmu-miR-200a-3p Runx1 1.19 1.60 1.77** 1.46
mmu-miR-200b-3p Runx1 1.22 1.32 1.07 -1.70
mmu-miR-203-3p Runx2 1.12 -1.14 -1.18 -1.07
mmu-miR-204-5p Runx2 1.27 1.56 1.28 -1.61
mmu-miR-205-5p Runx1/Runx2 -1.47* -2.64** -2.94** -4.35*
mmu-miR-214-3p Runx1 -1.11 -1.48 -1.70 -1.76
mmu-miR-218-5p Runx2 -1.22 -1.30 -1.16 -1.72
mmu-miR-221-3p Runx2 -1.20 -1.45 -1.56* -2.17*
mmu-miR-320-3p Runx1/Runx2 -1.23* -1.22 -1.67 -1.82
mmu-miR-324-5p Runx2 -1.19 -1.09 -1.27 -1.49
mmu-miR-340-5p Runx1/Runx2 1.38 2.39 2.53** 2.06
mmu-miR-375-3p Runx1/Runx2 -1.27*** -1.96 -3.03* -6.67**
mmu-miR-382-5p Runx1 -1.33 -1.28 -2.50** -2.22*
mmu-miR-384-5p Runx1/Runx2 1.15 1.15 -2.38* -2.94*
The levels of 28 selected miRNAs predicted to target Runx1, Runx2, or both (TargetScan v6.2) were determined by 
qPCR. Seven miRNA (bold) are downregulated at least 2-fold in TRAMP prostate as compared to wild type at either 
16 or 21 week old animals. Fold change is calculated as TRAMP expression as compared wild type at each time point. 
Expression normalized to U6. N = 3 animals per time point per genotype. * p < 0.05; ** p < 0.01; *** p < 0.001.
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towards mutual exclusion [15, 17]. The latter is consistent 
with the observed upregulation of Runx1 and Runx2 when 
PTEN is downregulated by 21 weeks in the diseased 
TRAMP prostate (Figure 1A, 1B, 1G), while the former 
supports the proposed idea that mutual activation of Runx 
and PI3K/AKT signaling promotes tumor progression [2].
DISCUSSION
The goal of our study is to elucidate mechanisms 
underlying the deregulated expression of Runx factors 
during PCa progression. Here, we identify miRNAs 
targeting Runx factors with reciprocal changes that reflect 
abnormal Runx expression levels at stages of advancing 
tumorigenesis in the TRAMP mouse. Our study, for the 
first time, identifies changes in Runx1 and Runx2 that 
are associated with molecular markers of human prostate 
cancer progression. The significant findings of our study 
relating TRAMP mouse to human prostate cancer include: 
1) a transition stage from androgen-sensitive to androgen-
insensitive disease as indicated by loss of PTEN and 
the androgen receptor; 2) constitutively elevated Runx1 
and Runx2 in PCa with reciprocal downregulation of 
seven Runx-targeting miRNAs, as compared to wild 
type; 3) functionally, both Runx1 and Runx2, when 
downregulated, reduce cell motility; 4) miRNAs targeting 
Runx1 and Runx2 also target genes linked to other PCa 
associated pathways, including Wnt, TGF-β, p53, IGF, 
EGF, VEGF that are all known to be regulated by Runx 
factors [13, 59]; and 5) the interaction network based on 
Runx1, Runx2, and Runx-targeting miRNAs is centered 
on PI3K/AKT signaling.
The funneling of downregulated miRNAs targeting 
Runx factors and other gene targets revealed in the 
Prostate Cancer Signaling network identify molecular 
interactions with key signaling pathways promoting 
tumor growth similar to human PCa progression (Figure 
5, e.g., PI3K, AKT, ERK, p53, RB/E2F). Specific and 
coordinated activities of Runx1 and Runx2 are identified 
during prostate tumorigenesis. The presence of miRNAs 
targeting Runx1 and/or Runx2 in normal prostate tissue 
and the complete absence of these miRNAs in prostate 
tumors upregulates both Runx1 and Runx2 as well as 
AKT signaling. Progression through AKT signaling in 
Figure 3: Runx-targeting miRNAs have reciprocal expression trends to Runx factors during PCa progression. Of the 
28 miRNAs screened in Table 1 in (A), seven miRNAs predicted to target Runx1, Runx2, or both are downregulated in TRAMP prostates 
as compared to age-matched, non-transgenic control animals. In (B), fold change is calculated as TRAMP expression compared wild type 
at each time point. mRNA expression normalized to 18S and miRNA expression normalized to U6. N = 3 animals per time per genotype. 
Error bars are not shown for simplicity.
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highly relevant to human PCa. Phosphorylation of Runx2 
increases Runx2 transcriptional activity [2], and occurs in 
response to most growth factor signaling as confirmed in 
PCa by pathway analysis (see Figure 4C).
The impact of our study not only elucidates the 
involvement of Runx1 and Runx2 during tumorigenesis, 
but also identifies stages of disease progression at the 
molecular level within the TRAMP model system. The 
initial upregulation of both Runx1 and Runx2 that we 
describe here, parallels the increase in AR previously 
reported in androgen-dependent human PCa [60, 61]. 
Most significant to human PCa is the change that we 
identify in the TRAMP mouse, for the first time that occurs 
between 16 and 21 weeks as the disease transitions from 
AR positive to AR negative tumors. In Table 1, numerous 
miRNAs tied to androgen response in PCa are strikingly 
downregulated, such as miR-27b-3p, miR-141-3p, miR-
181a-5p, miR-221-3p, and miR-375-3p. Consistent with 
these observations is the fact that miRNAs predicted to 
target AR, such as miR-23b-5p, miR-181-5p, and miR-
205-5p are constitutively reduced in TRAMP prostates. 
Importantly, these miRNAs also target Runx factors. Thus, 
Figure 4: Biological pathway analysis of genes in the Runx/miRNA interaction network. The computational workflow 
used to discover enriched pathways is outlined in (A) Genes that interact directly or indirectly with Runx1, Runx2, or the seven candidate 
miRNAs were identified in IPA and exported. These nine lists were combined into List A containing 3569 genes. List A genes were upload in 
DAVID v6.7, annotated for function, and databases queried to identify pathway enrichment ranked by EASE score (modified Fisher Exact 
test). List A contains ~18% of the genes within the KEGG database and ~25% contained in the PANTHER database. The top 10 KEGG 
pathways are shown in (B) and 16 PANTHER pathways with an EASE score < 0.05 shown in (C) *Score is the –log
10
(EASE score). †FE 
is fold enrichment within List A as compared to all annotated genes within each database. ‡miR-384-5p has over 1000 gene interactions in 
IPA. Only the top 1000 were used in our analysis.
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the inflection point of disease progression between 16 and 
21 weeks marked by the loss of AR is coupled to further 
de-repression of Runx1 and Runx2. The combined effects 
of loss of miRNAs in prostate tumors that regulate AR and 
Runx in normal prostate tissue, contribute to tumorigenesis 
in the TRAMP mouse, mirroring that of human disease. 
Given these findings, the TRAMP mouse can be used 
to pursue the mechanisms contributing to this dramatic 
change in PCa markers to enhance our understanding of 
disease progression. Moreover, Runx-targeting miRNAs 
inform a regulatory network that translates to an improved 
understanding of prostate biology and novel options for 
prostate cancer diagnosis and directed therapy.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
Figure 5: Runx1/2 and targeting miRNA molecular interactions in Prostate Cancer Signaling network. Genes that interact 
with Runx1, Runx2, and selected Runx targeting miRNAs (Figures 3, 4) were identified using IPA (www.ingenuity.com) and mapped to 
the Prostate Cancer Signaling network. Orange genes interact with Runx1; Green genes interact with Runx2; Red genes interact with both 
Runx1 and Runx2. Blue boxes highlight PI3K/AKT/PTEN and control of cell growth as centers through which Runx1, Runx2, and Runx-
targeting miRNAs function.
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institutional review board. In conducting research using 
animals, the investigators adhere to the laws of the United 
States and regulations of the Department of Agriculture.
Mice
Hemizygous females C57BL/6-Tg(TRAMP) 
8247Ng/J (strain 003135, The Jackson Laboratory) were 
crossed with wild type C57BL/6 males. All animals were 
genotyped using the following PCR primers: Transgene 
oIMR7084: 5’-GCGCTGCTGACTTTCTAAACATAA 
G-3’; Transgene oIMR7085: 5’-GAGCTCACGTTA
AGTTTTGATGTGT-3’; Int. pos. CTL F oIMR7338: 
5’-CTAGGCCACAGAATTGAAAGATCT-3’; Int. pos. 
CTL R oIMR7339: 5’-GTAGGTGGAAATTCTAGCAT
CATCC-3’. All animals were housed in a pathogen-free 
environment and handled according to protocol number 
12-054 approved by the Institutional Animal Care and Use 
Committee at the University of Vermont.
Dissection of ventral and lateral murine 
prostate lobes
Prostate lobes were removed as previously described 
[62].
RNA isolation
Prostate lobes were washed in 1X PBS and 
transferred to 1 mL QIAzol (QIAGEN) for tissue 
homogenization. Tissue was homogenized on ice 
in three to six 5-second bursts with a Polytron 
2100 homogenizer with a 7mm tip on setting 25. 
Homogenized tissue in QIAzol was stored at -80°C 
until RNA isolated. RNA was isolated with the 
miRNeasy Mini kit (QIAGEN) following manufacture’s 
protocol. RNA quality was assessed on an Agilent 2100 
Bioanalyzer using RNA Nano chips based on the RIN 
number, ratio of 28S/18S, and presence of distinct of 
18S and 28S peaks with lack of RNA fragments less 
than 1000 nucleotides.
Quantitative RT-PCR
cDNA for miRNA and mRNA was prepared 
separately using 1000ng of RNA. mRNA cDNA was 
synthesized with the SuperScript III First-Strand Kit (Life 
Technologies) and miRNA cDNA was synthesized with 
the miScript II RT Kit (QIAGEN) using the HiSpec buffer 
following the recommended manufacturer’s protocol. 
All qPCR was performed in 384-well plates on an ABI 
ViiA7 machine using iTaq Universal SYBR Green (Bio-
Rad) or QuantiTect SYBR Green (QIAGEN) for mRNA 
and miRNA respectively. Data was normalized to 
expression of 18S and U6. Forward miRNA primer and 
forward and reverse mRNA primer sequences are listed in 
Supplementary Table S2.
Cell culture and transfection
TRAMP-C2 cells, an epithelial line isolated from 
tumor burdened TRAMP prostates, were maintained 
in High-Glucose DMEM (Hyclone) supplemented 
with 0.005 mg/ml bovine insulin (Sigma), 10nM 
dehydroisoandrosterone (Sigma), 5% fetal bovine serum 
(Atlanta), 5% Nu-Serum IV (Corning), and 1% penicillin/
streptomycin (Life Technologies). One day prior to 
transfection, cells were plated at 4 x 105 cells/well in 
6-wells plates. 50nM Dharmacon ON-TARGETplus 
SMARTpools for non-targeting control #1 (D-001810-01-
05), siRunx1 (L-048982-00), or siRunx2 (L-012665-00-
0005) were transfected into cells with Lipofectamine 2000 
(Life Technologies) as per manufacturers recommended 
protocol.
Migration assay
Following transfection, cells were incubated 
overnight in reduced serum media (1% FBS and 1% Nu-
Serum IV). A scratch along the diameter of each well 
was made in the cell monolayer with a 200μL pipet tip 
and sufficiently washed to remove floating debris. Three 
pre-marked locations were imaged along each scratch at 
four-hour intervals for 20 hours. Images were acquired in 
SPOT Imaging Solutions Software v5.0 from a SPOT RT3 
2Mp Monochrome camera (Diagnostic Instruments, Inc.) 
attached to an Eclipse TS100 (Nikon) microscope using a 
10X/0.30 Plan Fluor objective (Nikon). Scratch area was 
measured with the MiToBo plug-in for ImageJ (Fiji) using 
default settings.
Bioinformatics
Candidate miRNAs targeting Runx1 and Runx2 
were identified using TargetScan v6.2 (www.targetscan.
com). IPA (www.ingenuity.com QIAGEN) was used to 
identify molecular interaction networks of Runx1, Runx2, 
and selected miRNAs. Gene lists were compiled into one 
dataset and analyzed with DAVID v6.7 (https://david.
ncifcrf.gov/) using default settings.
Statistics
All data were graphed and analyzed using Prism 
v6 (GraphPad Software) to calculate SEM and p-values 
(unpaired t-test).
ACKNOWLEDGMENTS
The authors would like to thank Drs. Steven Ades 
and Scott Perrapato for their insight and guidance on 
prostate cancer diagnosis, treatment, and needs in the 
clinic, Kristiaan Finstad for all mouse husbandry and aid 
in prostate dissections, Dr. Jon Ramsey in the Clinical 
Translational Research Laboratory at the University of 
Oncotarget70472www.impactjournals.com/oncotarget
Vermont Cancer Center for providing siRNA against 
Runx2, and all members of our laboratory for their helpful 
comments and suggestions in preparing this manuscript.
Areg Zingiryan’s present address: Department 
of Medicine, Internal Medicine, Lewis Katz School of 
Medicine, Temple University, Philadelphia, PA 19122.
CONFLICTS OF INTEREST
The authors declare no conflicts.
GRANT SUPPORT
This work was supported by a Department of 
Defense CDRMP PCRP Postdoctoral Fellowship 
W81XWH-14-1-0468 to NHF, and by National Institutes 
of Health grants R37 DE012528 to JBL, P01 CA140043 to 
GSS, JBL, and LRL and P01 CA082834 to GSS and JBL.
REFERENCES
1. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson 
AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone 
AM, Henley SJ, Eheman CR, Anderson RN, et al. Annual 
Report to the Nation on the Status of Cancer, 1975-2011, 
Featuring Incidence of Breast Cancer Subtypes by Race/
Ethnicity, Poverty, and State. J Natl Cancer Inst. 2015; 107: 
djv048.
2. Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and 
the PI3K/AKT axis reciprocal activation as a driving force 
for tumor progression. Mol Cancer. 2015; 14: 137.
3. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley 
WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, 
Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl 
Acad Sci U S A. 1995; 92: 3439-3443.
4. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo 
FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg 
NM. Metastatic prostate cancer in a transgenic mouse. 
Cancer Res. 1996; 56: 4096-4102.
5. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, 
Stein JL, Stein GS. Regulatory roles of Runx2 in metastatic 
tumor and cancer cell interactions with bone. Cancer 
Metastasis Rev. 2006; 25: 589-600.
6. Ito Y, Bae SC, Chuang LS. The RUNX family: 
developmental regulators in cancer. Nat Rev Cancer. 2015; 
15: 81-95.
7. Voronov D, Gromova A, Liu D, Zoukhri D, Medvinsky 
A, Meech R, Makarenkova HP. Transcription factors 
Runx1 to 3 are expressed in the lacrimal gland epithelium 
and are involved in regulation of gland morphogenesis 
and regeneration. Invest Ophthalmol Vis Sci. 2013; 54: 
3115-3125.
8. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, 
Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, 
Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng 
S, et al. Sequence analysis of mutations and translocations 
across breast cancer subtypes. Nature. 2012; 486: 405-409.
9. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van 
Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, 
Crowder R, et al. Whole-genome analysis informs breast 
cancer response to aromatase inhibition. Nature. 2012; 486: 
353-360.
10. Ferrari N, Mohammed ZM, Nixon C, Mason SM, Mallon E, 
McMillan DC, Morris JS, Cameron ER, Edwards J, Blyth 
K. Expression of RUNX1 correlates with poor patient 
prognosis in triple negative breast cancer. PLOS ONE. 
2014; 9: e100759.
11. Browne G, Taipaleenmaki H, Stein GS, Stein JL, Lian 
JB. MicroRNAs in the control of metastatic bone disease. 
Trends Endocrinol Metab. 2014; 25: 320-327.
12. Lin TC, Su CY, Wu PY, Lai TC, Pan WA, Jan YH, Chang 
YC, Yeh CT, Chen CL, Ger LP, Chang HT, Yang CJ, Huang 
MS, et al. The nucleolar protein NIFK promotes cancer 
progression via CK1alpha/beta-catenin in metastasis and 
Ki-67-dependent cell proliferation. Elife. 2016; 5.
13. Pratap J, Lian JB, Stein GS. Metastatic bone disease: role 
of transcription factors and future targets. Bone. 2011; 48: 
30-36.
14. Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang W, Jafferji 
M, Gordon JA, Li Z, Croce CM, van Wijnen AJ, Stein JL, 
Stein GS, Lian JB. miR-218 directs a Wnt signaling circuit 
to promote differentiation of osteoblasts and osteomimicry 
of metastatic cancer cells. J Biol Chem. 2012; 287: 
42084-42092.
15. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy 
BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin 
Y, Reva B, Goldberg AP, et al. The cBio cancer genomics 
portal: an open platform for exploring multidimensional 
cancer genomics data. Cancer Discov. 2012; 2: 401-404.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, 
Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami 
E, Sander C, Schultz N. Integrative analysis of complex 
cancer genomics and clinical profiles using the cBioPortal. 
Sci Signal. 2013; 6: pl1.
17. Cancer Genome Atlas Research Network. The Molecular 
Taxonomy of Primary Prostate Cancer. Cell. 2015; 163: 
1011-1025.
18. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, 
Quinn J, Aronow BJ, Abate-Shen C. Prolonged exposure 
to reduced levels of androgen accelerates prostate cancer 
progression in Nkx3.1; Pten mutant mice. Cancer Res. 
2007; 67: 9089-9096.
19. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, 
Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri 
DC, Pratap J, Keller E, Stein GS, et al. Runx2 association 
with progression of prostate cancer in patients: mechanisms 
mediating bone osteolysis and osteoblastic metastatic 
lesions. Oncogene. 2010; 29: 811-821.
Oncotarget70473www.impactjournals.com/oncotarget
20. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams 
BJ, Glass J, Davis JN, Meyers S. RUNX1 (AML-1) and 
RUNX2 (AML-3) cooperate with prostate-derived Ets 
factor to activate transcription from the PSA upstream 
regulatory region. J Cell Biochem. 2006; 97: 1-17.
21. Dutta A, Li J, Lu H, Akech J, Pratap J, Wang T, Zerlanko 
BJ, FitzGerald TJ, Jiang Z, Birbe R, Wixted J, Violette SM, 
Stein JL, et al. Integrin alphavbeta6 promotes an osteolytic 
program in cancer cells by upregulating MMP2. Cancer 
Res. 2014; 74: 1598-1608.
22. Browne G, Taipaleenmaki H, Bishop NM, Madasu SC, 
Shaw LM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 
Runx1 is associated with breast cancer progression in 
MMTV-PyMT transgenic mice and its depletion in vitro 
inhibits migration and invasion. J Cell Physiol. 2015; 230: 
2522-2532.
23. Zhang X, Wu H, Dobson JR, Browne G, Hong D, Akech 
J, Languino LR, Stein GS, Lian JB. Expression of the 
IL-11 gene in metastatic cells is supported by Runx2-Smad 
and Runx2-cJun complexes induced by TGFbeta1. J Cell 
Biochem. 2015; 116: 2098-2108.
24. Shi M, Liu D, Duan H, Shen B, Guo N. Metastasis-related 
miRNAs, active players in breast cancer invasion, and 
metastasis. Cancer Metastasis Rev. 2010; 29: 785-799.
25. Taipaleenmaki H, Browne G, Akech J, Zustin J, van Wijnen 
AJ, Stein JL, Hesse E, Stein GS, Lian JB. Targeting of 
Runx2 by miR-135 and miR-203 Impairs Progression of 
Breast Cancer and Metastatic Bone Disease. Cancer Res. 
2015; 75: 1433-1444.
26. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, 
Vousden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan 
BS, Giaccone G, Lowe SW, Takahashi N, et al. Loss of 
p63 and its microRNA-205 target results in enhanced cell 
migration and metastasis in prostate cancer. Proc Natl Acad 
Sci U S A. 2012; 109: 15312-15317.
27. Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, 
Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, 
Hackermuller J. MiR-130a, miR-203 and miR-205 jointly 
repress key oncogenic pathways and are downregulated in 
prostate carcinoma. Oncogene. 2013; 32: 277-285.
28. Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci 
A, Francescangeli F, Pecci R, Muto G, Collura D, Bedini 
R, Zeuner A, Valtieri M, Sentinelli S, et al. A microRNA 
code for prostate cancer metastasis. Oncogene. 2016; 35: 
1180-1192.
29. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn 
NH, Li Y. MicroRNA-21 promotes cell transformation by 
targeting the programmed cell death 4 gene. Oncogene. 
2008; 27: 4373-4379.
30. Darimipourain M, Wang S, Ittmann M, Kwabi-Addo B. 
Transcriptional and post-transcriptional regulation of 
Sprouty1, a receptor tyrosine kinase inhibitor in prostate 
cancer. Prostate Cancer Prostatic Dis. 2011; 14: 279-285.
31. Mishra S, Lin CL, Huang TH, Bouamar H, Sun LZ. 
MicroRNA-21 inhibits p57Kip2 expression in prostate 
cancer. Mol Cancer. 2014; 13: 212.
32. Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga 
VG, Paulus E, Davidoff AM, Pfeffer LM. The oncogenic 
microRNA-21 inhibits the tumor suppressive activity of 
FBXO11 to promote tumorigenesis. J Biol Chem. 2015; 
290: 6037-6046.
33. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, 
Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R. 
Regulatory role of mir-203 in prostate cancer progression 
and metastasis. Clin Cancer Res. 2011; 17: 5287-5298.
34. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann 
MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt 
N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of 
genetically engineered mice: definitions and classification. 
The consensus report from the Bar Harbor meeting of the 
Mouse Models of Human Cancer Consortium Prostate 
Pathology Committee. Cancer Res. 2004; 64: 2270-2305.
35. Jeet V, Russell PJ, Khatri A. Modeling prostate cancer: a 
perspective on transgenic mouse models. Cancer Metastasis 
Rev. 2010; 29: 123-142.
36. Irshad S, Abate-Shen C. Modeling prostate cancer in mice: 
something old, something new, something premalignant, 
something metastatic. Cancer Metastasis Rev. 2013; 32: 
109-122.
37. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, 
Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, 
Loda M, Thomas G, Borowsky A, et al. Animal models of 
human prostate cancer: the consensus report of the New 
York meeting of the Mouse Models of Human Cancers 
Consortium Prostate Pathology Committee. Cancer Res. 
2013; 73: 2718-2736.
38. Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, 
Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani 
MS. Gene expression profile of mouse prostate tumors reveals 
dysregulations in major biological processes and identifies 
potential murine targets for preclinical development of human 
prostate cancer therapy. Prostate. 2008; 68: 1517-1530.
39. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, 
Macfarlane RJ, Chi KN, Marshall VR, Tilley WD, Butler 
LM. Discovery of circulating microRNAs associated with 
human prostate cancer using a mouse model of disease. Int 
J Cancer. 2012; 131: 652-661.
40. Petrylak DP. Current state of castration-resistant prostate 
cancer. Am J Manag Care. 2013; 19: s358-365.
41. Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, van 
Wijnen AJ, Jiang Z, Stein GS. Prostate cancer regulatory 
networks. J Cell Biochem. 2009; 107: 845-852.
42. Song H, Zhang B, Watson MA, Humphrey PA, Lim 
H, Milbrandt J. Loss of Nkx3.1 leads to the activation 
of discrete downstream target genes during prostate 
tumorigenesis. Oncogene. 2009; 28: 3307-3319.
Oncotarget70474www.impactjournals.com/oncotarget
43. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, 
Sellers WR. Loss of PTEN expression in paraffin-embedded 
primary prostate cancer correlates with high Gleason score 
and advanced stage. Cancer Res. 1999; 59: 4291-4296.
44. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta 
in the tumour microenvironment. Nat Rev Cancer. 2013; 
13: 788-799.
45. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 
20 years after. Curr Opin Oncol. 2013; 25: 52-58.
46. Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D. 
Activation of Akt signaling in prostate induces a TGFbeta-
mediated restraint on cancer progression and metastasis. 
Oncogene. 2014; 33: 3660-3667.
47. Gao M, Ossowski L, Ferrari AC. Activation of Rb and 
decline in androgen receptor protein precede retinoic acid-
induced apoptosis in androgen-dependent LNCaP cells and 
their androgen-independent derivative. J Cell Physiol. 1999; 
179: 336-346.
48. van der Deen M, Akech J, Lapointe D, Gupta S, Young 
DW, Montecino MA, Galindo M, Lian JB, Stein JL, Stein 
GS, van Wijnen AJ. Genomic promoter occupancy of runt-
related transcription factor RUNX2 in Osteosarcoma cells 
identifies genes involved in cell adhesion and motility. J 
Biol Chem. 2012; 287: 4503-4517.
49. Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, 
Liuzzi F, Croce CM, Brunetti E, Grignani F, Peschle C. 
MicroRNAs 17-5p-20a-106a control monocytopoiesis 
through AML1 targeting and M-CSF receptor upregulation. 
Nat Cell Biol. 2007; 9: 775-787.
50. Zhang Y, Xie RL, Croce CM, Stein JL, Lian JB, van Wijnen 
AJ, Stein GS. A program of microRNAs controls osteogenic 
lineage progression by targeting transcription factor Runx2. 
Proc Natl Acad Sci U S A. 2011; 108: 9863-9868.
51. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman 
MS, Chang I, Yamamura S, Tanaka Y, Deng G, Dahiya R. 
miR-23b represses proto-oncogene Src kinase and functions 
as methylation-silenced tumor suppressor with diagnostic 
and prognostic significance in prostate cancer. Cancer Res. 
2012; 72: 6435-6446.
52. Coarfa C, Fiskus W, Eedunuri VK, Rajapakshe K, Foley 
C, Chew SA, Shah SS, Geng C, Shou J, Mohamed JS, 
O’Malley BW, Mitsiades N. Comprehensive proteomic 
profiling identifies the androgen receptor axis and other 
signaling pathways as targets of microRNAs suppressed in 
metastatic prostate cancer. Oncogene. 2016; 35: 2345-2356.
53. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer 
N, Eklund AC, Han J, Nemunaitis J. MicroRNA profile 
analysis of human prostate cancers. Cancer Gene Ther. 
2009; 16: 206-216.
54. Filella X, Foj L. miRNAs as novel biomarkers in the 
management of prostate cancer. Clin Chem Lab Med. 
2016; 0.
55. Sanchez CA, Andahur EI, Valenzuela R, Castellon EA, 
Fulla JA, Ramos CG, Trivino JC. Exosomes from bulk and 
stem cells from human prostate cancer have a differential 
microRNA content that contributes cooperatively over local 
and pre-metastatic niche. Oncotarget. 2016; 7: 3993-4008. 
doi: 10.18632/oncotarget.6540.
56. Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ, Wang Y. miR-
382 inhibits tumor growth and enhance chemosensitivity 
in osteosarcoma. Oncotarget. 2014; 5: 9472-9483. doi: 
10.18632/oncotarget.2418.
57. Huang da W, Sherman BT, Lempicki RA. Systematic 
and integrative analysis of large gene lists using DAVID 
bioinformatics resources. Nat Protoc. 2009; 4: 44-57.
58. Huang da W, Sherman BT, Lempicki RA. Bioinformatics 
enrichment tools: paths toward the comprehensive 
functional analysis of large gene lists. Nucleic Acids Res. 
2009; 37: 1-13.
59. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, 
Huser C, Stein T, Neil J, Cameron ER. Runx2 in normal 
tissues and cancer cells: A developing story. Blood Cells 
Mol Dis. 2010; 45: 117-123.
60. Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge 
NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, 
Schones DE, Frenkel B. Differential effects of RUNX2 
on the androgen receptor in prostate cancer: synergis-
tic stimulation of a gene set exemplified by SNAI2 
and subsequent invasiveness. Cancer Res. 2014; 74: 
2857-2868.
61. Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Urano T, 
Takahashi S, Homma Y, Aburatani H, Inoue S. RUNX1, 
an androgen- and EZH2-regulated gene, has differential 
roles in AR-dependent and -independent prostate 
cancer. Oncotarget. 2015; 6: 2263-2276. doi: 10.18632/
oncotarget.2949.
62. Zingiryan A, Farina NH, Finstad KH, Stein JL, Lian JB, 
Stein GS. Dissection of individual prostate lobes in mouse 
models of prostate cancer to obtain high quality RNA. J 
Cell Physiol. 2017; 232:14-8.
